Portfolio Planning When You Have Both Class II and Class III Device Programs Portfolio Planning When You Have Both Class II and Class III Device Programs Effective portfolio planning is integral to navigating the complex landscape of medical device regulation. When dealing with both Class II and Class III devices, a clear understanding of FDA pathways is essential. This guide outlines a step-by-step approach to regulatory pathway selection, focusing on medical device classification, 510(k), De Novo, and PMA pathways. Understanding Medical Device Classifications The foundation of any regulatory strategy is a thorough understanding of the classification of devices. The FDA…

Regulatory strategy workshop blueprint for early device pathway decisions Regulatory Strategy Workshop Blueprint for Early Device Pathway Decisions In the dynamic landscape of medical devices, a clear understanding of regulatory pathways is critical for successful product development and market entry. This comprehensive guide outlines a regulatory strategy workshop blueprint for early device pathway decisions, highlighting the FDA’s classification system, the 510(k), De Novo, and PMA pathways. The audience for this article includes regulatory, quality, clinical, and RA/QA professionals in the medical device and combination products sectors. Understanding Medical Device Classification The first step in determining the regulatory pathway for a…

Refuse to Accept RTA Checklists for 510(k), De Novo, and PMA Dossiers Refuse to Accept RTA Checklists for 510(k), De Novo, and PMA Dossiers In the realm of medical devices, classification and regulatory pathways are crucial elements for ensuring compliance with FDA requirements. Specifically, the 510(k), De Novo, and PMA (Premarket Approval) submissions represent distinct pathways for gaining access to the U.S. market. However, many manufacturers find themselves navigating the complexities of the Refuse to Accept (RTA) checklists issued by the FDA. This article serves as a comprehensive regulatory tutorial on how to approach these RTA checklists effectively, and what…

Combination Product Considerations When Choosing a Primary Device Pathway Introduction to Combination Products and Regulatory Pathways Combination products represent an essential segment of the medical product landscape, encompassing products that combine drug, device, and biological components into a single entity. Understanding the framework of the FDA regulatory pathways is crucial for professionals involved in the development and commercialization of these products. The FDA categorizes combination products based on their primary mode of action, leading to various regulatory pathways, including 510(k), De Novo, and premarket approval (PMA). This tutorial aims to explain the considerations necessary for regulatory pathway selection concerning combination…

Common 510(k) Review Issues and How to Avoid Additional Information Requests In the highly regulated landscape of medical devices, understanding the nuances of the 510(k) premarket notification process is essential for regulatory, quality, clinical, and RA/QA professionals. A careful submission to the U.S. Food and Drug Administration (FDA) can minimize review issues, notably requests for additional information (AI requests), which can significantly delay your device’s time to market. This tutorial provides a comprehensive, step-by-step approach to navigating the common medical device classification pathways including the 510(k), De Novo, and PMA pathways. Understanding the 510(k) Paradigm The 510(k) pathway allows manufacturers…